More Articles

Pfizer and India-based Biocon make biosimilar insulin deal Biosimilars/News | Posted 08/11/2010

Biocon, India’s largest biotechnology company by revenue and Pfizer—the world’s biggest pharma company—announced on 18 October 2010 that they have entered into a strategic global agreement for the...

UK scraps generic substitution plans Policies & Legislation | Posted 08/11/2010

The UK government has announced that it will not progress with plans to automatically substitute medications with generic drugs in primary care. Health Minister Lord Howe announced the decision on...

Slow response to internet sales of fake pharmaceuticals Generics/General | Posted 08/11/2010

If you are reading this news online, you are surely aware that many sites claim to sell “generic medicines” “without prescription” over the internet. Police and authorities have noticed as well, bu...

Spotlight on Bosnia Pharma News | Posted 08/11/2010

In today’s global business environment, companies battle for position all over the world. Today Bosnia’s pharmaceutical industry is making the headlines, with a battle to invest in the leading comp...

Teva continues to expand Generics/News | Posted 08/11/2010

The world's largest generic pharmaceutical company, Israeli-based Teva Pharmaceutical Industries, is investing Euros 42 million to expand its production plant in Stouffville, Canada. At the same ti...

Hurdles to entering the biosimilars’ market Biosimilars/General | Posted 08/11/2010

Yet more hurdles to entering the biosimilars’ market have been identified in a Reuters’ report. High development costs, complex manufacturing and legal hurdles are holding back generic drugmakers s...

Canadian guidelines for biosimilars Guidelines | Posted 29/10/2010

Last update: 10 August 2012The regulatory body for approval of medicines in Canada is the Therapeutic Products Directorate of Health Canada.Health Canada develops and enforces regulations under Can...

Comparison of biosimilar and branded vancomycin Generics/Research | Posted 29/10/2010

Despite demonstrating pharmacological equivalence, researchers have found biosimilar vancomycin exhibited inferior antimicrobial activity compared with the branded product.